Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

Please continue to report adverse events to the FDA when patients develop them while taking any of these new and older drugs. Working together, we can all improve patient care.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Berkrot B. FDA declines to expand approval of Pfizer arthritis drug. Reuters. 2015 Oct 14.
Pfizer Inc. News release: Pfizer receives complete response letter from FDA for oral XELJANZ (tofacitinib citrate) supplemental new drug application for moderate to severe chronic plaque psoriasis. 2015 Oct 14.
Institute for Safe Medical Practices. Executive summary—two anti-TNF products post most injury reports. ISMP Quarter Watch. 2015 Sep 23.

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Related Articles